Clinical trials: Depression in Remission
Depression, Major Depressive Disorder
Incomplete Response in Late-Life Depression: Getting to Remission With Buprenorphine
The purposes of this project are to examine the feasibility, safety, tolerability and clinical effect of low-dose buprenorphine as a novel treatment for late-life treatment-resistant depression and to develop preliminary data…
- Trial name
- IRLGREY-B (NCT02176291)
- Testing
- Buprenorphine
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Jordan F. Karp
Remission in Depression
Ketamine's Actions on Rumination Mechanisms as an Antidepressant
Rumination and anhedonia are two of the most common characteristics of depression that persist during remission and are not easily targeted by commonly prescribed antidepressants.
- Trial name
- KARMA (NCT04656886)
- Testing
- Intravenous Infusion
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- King's College London
Adjunct in the Treatment of Depressive Disorder
A Randomized, Open-Label, 52-Week Extension Study to Evaluate the Maintenance of Remission, Relapse Prevention, and Long-Term Safety of CreNeuroS™ in Patients With Major Depressive Disorder Who Achieved Remission Following an 8-Week Parent Study
This multicenter, randomized, open-label extension study will evaluate the maintenance of remission, relapse prevention, long-term clinical outcomes, and safety of CreNeuroS™ in participants with Major Depressive Disorder (MDD)…
- Trial name
- NCT07893002
- Testing
- No intervention, CreNeuroS™ CNS Fish Oil Plus Softgels, 1 capsule orally once daily, CreNeuroS™ CNS Fish Oil Plus Softgels, 2 capsule orally once daily
- Where
- India
- Volunteers
- 60 people
- Sponsor
- Sichuan Credit Pharmaceutical Co., Ltd.
Major Depressive Disorder
VA Augmentation and Switching Treatments for Improving Depression Outcomes
The overall purpose is to determine research based 'next-steps' for outpatients with major depressive disorder who have not had satisfactory outcomes to standard 'first-step' treatments.
- Trial name
- VAST-D (NCT01421342)
- Testing
- Switching: Bupropion-SR, Augmenting: Antidepressant + Bupropion-SR, Augmenting: Antidepressant + Aripiprazole
- Where
- 35 sites in United States
- Volunteers
- 1,522 people
- Sponsor
- VA Office of Research and Development
Major Depressive Disorder Remission, Major Depressive Disorder
Vulnerability Markers for Depression
The current study is a pilot for the GRF project entitled "Predicting illness trajectories in fully remitted major depression using concurrent TBS/fNIRS".
- Conditions
- Major Depressive Disorder Remission, Major Depressive Disorder, Healthy
- Trial name
- NCT06402422
- Testing
- Theta-burst stimulation
- Where
- Hong Kong
- Volunteers
- 166 people, healthy volunteers welcome
- Sponsor
- The Hong Kong Polytechnic University
Depression in Remission, Cognitive Computer Training
Cognitive Computer Training in Patients With Depression
Cognitive impairment plays an important role in functional recovery and leads to long-term sickness absence. Therefore there is a need of a treatment specifically improving cognitive functions.
- Conditions
- Depression in Remission, Cognitive Computer Training, Returning to Work
- Trial name
- NCT02821975
- Testing
- Cognitive computer training
- Where
- Denmark
- Volunteers
- 20 people
- Sponsor
- University of Southern Denmark
Cancer in Remission (Any Type or Stage), Depression
Repetitive Transcranial Magnetic Stimulation in Cancer Patients With Depression and Anxiety
Cancer is a leading cause of mortality and morbidity worldwide. In addition, cancer is associated with high rates of depression and anxiety among its sufferers, and cancer patients with depression usually have worse treatment…
- Conditions
- Cancer in Remission (Any Type or Stage), Depression, Anxiety
- Trial name
- rTMSinCP (NCT01701284)
- Testing
- Repetitive Transcranial Magnetic Stimulation (rTMS)
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Northwestern University
Depression
tDCS in the Prevention of Relapse After Electroconvulsive Therapy
While electroconvulsive therapy (ECT) in major depression is effective, high relapse rates and cognitive side effects limit its long-term use.
- Trial name
- NCT02886858
- Testing
- Device : Transcranial direct current stimulation
- Where
- France
- Volunteers
- 1 people
- Sponsor
- Hôpital le Vinatier
Depression, Bipolar Depression
Efficacy of Convulsive Therapies During Continuation
This trial aims to assess the efficacy and tolerability of Magnetic Seizure Therapy (MST) and two different forms of electroconvulsive therapy (ECT) in sustaining response during and after a course of continuation treatment.
- Conditions
- Depression, Bipolar Depression, Unipolar Depression, Treatment Resistant Depression
- Trial name
- CORRECT-C (NCT03711019)
- Testing
- Magnetic Seizure Therapy (MST), RUL-UB ECT, Bitemporal ECT
- Where
- 3 sites in Canada
- Volunteers
- 106 people
- Sponsor
- Centre for Addiction and Mental Health
Major Depressive Disorder
Does Dual Therapy Hasten Antidepressant Response?
This study will utilize a randomized double-blind design to evaluate whether initial treatment with two anti-depressant medications (escitalopram and bupropion) results in more rapid remission and greater over-all remission rates…
- Trial name
- NCT00519428
- Testing
- escitalopram, bupropion extra long (XL), escitalopram + bupropion
- Where
- 2 sites in United States, Canada
- Volunteers
- 245 people
- Sponsor
- New York State Psychiatric Institute
Depression
Maintenance Interpersonal Psychotherapy for Sustaining Remission of Depression
This study will evaluate the effectiveness of maintenance interpersonal psychotherapy (IPT) in preventing relapse of depression in women who have required combined psychotherapy and pharmacotherapy treatment to obtain a remission…
- Trial name
- NCT00227981
- Testing
- Interpersonal Psychotherapy, Fluoxetine
- Where
- United States
- Volunteers
- 93 people
- Sponsor
- University of Pittsburgh
Depression
Determining Optimal Continuation Treatment Duration for Depressed Children and Adolescents
This study will determine the optimal length of continuation treatment with fluoxetine for children and adolescents with major depressive disorder, as well as the factors that may contribute to positive response during acute and…
- Trial name
- NCT00332787
- Testing
- Fluoxetine
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- University of Texas Southwestern Medical Center
Cancer
Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain
RATIONALE: Ketamine hydrochloride may lessen neuropathic pain in patients with cancer. It is not yet known whether ketamine hydrochloride given together with the best pain management is more effective than a placebo given…
- Trial name
- NCT01316744
- Testing
- ketamine hydrochloride, pharmacogenomic studies, questionnaire administration
- Where
- 3 sites in United Kingdom
- Volunteers
- 214 people
- Sponsor
- University of Glasgow
Cognitive Remediation, Cognitive Impairment
Internet-delivered Intervention Targeting Residual Cognitive Symptoms After Major Depressive Disorder
Background: Cognitive impairment and difficulties are frequently observed in individuals suffering from major depressive disorder. These impairments and difficulties can persist into remission as residual cognitive symptoms.
- Conditions
- Cognitive Remediation, Cognitive Impairment, Major Depression in Remission
- Trial name
- RestDep (NCT04864353)
- Testing
- RestDep: Internet-delivered intervention targeting residual cognitive symptoms
- Where
- Norway
- Volunteers
- 44 people
- Sponsor
- Haukeland University Hospital
Major Depressive Disorder, Insomnia
Time to Remission of Depressive Symptoms With Combined SSRI and Ramelteon
Hypothesis I: Patients in the SSRI + ramelteon treatment group will achieve remission (defined as an IDS-C30 score of 11 or less) more quickly than those in the SSRI + placebo group.
- Trial name
- TAKEDA (NCT00642694)
- Testing
- Escitalopram, Ramelteon
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- University of Texas Southwestern Medical Center
Depression, Clinical Depression
A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Depression
This study seeks to correlate microbiome sequencing data with information provided by patients and their medical records
- Conditions
- Depression, Clinical Depression, Depression, Anxiety, Depression, Postpartum
- Trial name
- NCT04211467
- Testing
- No Intervention
- Where
- United States
- Sponsor
- ProgenaBiome
Depression
Comparing Various Treatments for Achieving and Maintaining Remission of Depression
This study will evaluate the effectiveness of five combinations of drug therapy and psychotherapy in maintaining remission of depression symptoms in people with recurrent major depression.
- Trial name
- NCT00227955
- Testing
- Imipramine, Interpersonal Psychotherapy
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- University of Pittsburgh
Posttraumatic Stress Disorder
Exploring Efficacy of Multi-Mode Cognitive Processing Therapy (CPT) for PTSD
This study is a longitudinal, multicenter, single-blind, two-arm randomized controlled trial designed to evaluate the effectiveness of Multi-Modal Cognitive Processing Therapy (MMCPT) for individuals with posttraumatic stress…
- Trial name
- PTSD (NCT07105345)
- Testing
- Cognitive Processing Therapy (CPT), Treatment as Usual (TAU)
- Where
- Taiwan
- Volunteers
- 60 people
- Sponsor
- Far Eastern Memorial Hospital
Major Depressive Disorder, Depression
Incomplete Response in Late-Life Depression: Getting to Remission With Buprenorphine
The Investigators are conducting a research study to learn about the safety and benefit of using a medication called buprenorphine for patient with difficult to treat depression .
- Trial name
- (IRLGREY-B) (NCT02263248)
- Testing
- venlafaxine, buprenorphine
- Where
- Canada
- Volunteers
- 56 people
- Sponsor
- Centre for Addiction and Mental Health
Major Depressive Disorder, Recurrent, in Remission
Light and Ion Maintenance In Treatment for Depression (LIMIT-D): Feasibility Study
Antidepressants are widely used as first-line treatments for major depressive disorder (MDD). Clinical guidelines recommend 6-24 months of "maintenance" antidepressant treatment, after patients achieve symptom remission, to…
- Trial name
- NCT05423275
- Testing
- Negative ion therapy, Light therapy
- Where
- Canada
- Volunteers
- 100 people
- Sponsor
- University of British Columbia